S&P 500   4,966.81 (-0.88%)
DOW   37,990.25 (+0.57%)
QQQ   414.07 (-2.21%)
AAPL   165.08 (-1.17%)
MSFT   399.12 (-1.27%)
META   477.67 (-4.81%)
GOOGL   153.59 (-1.55%)
AMZN   173.95 (-2.94%)
TSLA   146.60 (-2.22%)
NVDA   764.87 (-9.67%)
AMD   146.22 (-5.71%)
NIO   3.80 (-5.00%)
BABA   69.02 (+0.20%)
T   16.47 (+0.86%)
F   12.09 (+0.25%)
MU   106.31 (-5.02%)
GE   148.30 (-3.03%)
CGC   8.02 (+2.43%)
DIS   112.11 (-0.28%)
AMC   3.14 (+7.53%)
PFE   25.96 (+2.24%)
PYPL   61.87 (-0.37%)
XOM   119.88 (+1.15%)
S&P 500   4,966.81 (-0.88%)
DOW   37,990.25 (+0.57%)
QQQ   414.07 (-2.21%)
AAPL   165.08 (-1.17%)
MSFT   399.12 (-1.27%)
META   477.67 (-4.81%)
GOOGL   153.59 (-1.55%)
AMZN   173.95 (-2.94%)
TSLA   146.60 (-2.22%)
NVDA   764.87 (-9.67%)
AMD   146.22 (-5.71%)
NIO   3.80 (-5.00%)
BABA   69.02 (+0.20%)
T   16.47 (+0.86%)
F   12.09 (+0.25%)
MU   106.31 (-5.02%)
GE   148.30 (-3.03%)
CGC   8.02 (+2.43%)
DIS   112.11 (-0.28%)
AMC   3.14 (+7.53%)
PFE   25.96 (+2.24%)
PYPL   61.87 (-0.37%)
XOM   119.88 (+1.15%)
S&P 500   4,966.81 (-0.88%)
DOW   37,990.25 (+0.57%)
QQQ   414.07 (-2.21%)
AAPL   165.08 (-1.17%)
MSFT   399.12 (-1.27%)
META   477.67 (-4.81%)
GOOGL   153.59 (-1.55%)
AMZN   173.95 (-2.94%)
TSLA   146.60 (-2.22%)
NVDA   764.87 (-9.67%)
AMD   146.22 (-5.71%)
NIO   3.80 (-5.00%)
BABA   69.02 (+0.20%)
T   16.47 (+0.86%)
F   12.09 (+0.25%)
MU   106.31 (-5.02%)
GE   148.30 (-3.03%)
CGC   8.02 (+2.43%)
DIS   112.11 (-0.28%)
AMC   3.14 (+7.53%)
PFE   25.96 (+2.24%)
PYPL   61.87 (-0.37%)
XOM   119.88 (+1.15%)
S&P 500   4,966.81 (-0.88%)
DOW   37,990.25 (+0.57%)
QQQ   414.07 (-2.21%)
AAPL   165.08 (-1.17%)
MSFT   399.12 (-1.27%)
META   477.67 (-4.81%)
GOOGL   153.59 (-1.55%)
AMZN   173.95 (-2.94%)
TSLA   146.60 (-2.22%)
NVDA   764.87 (-9.67%)
AMD   146.22 (-5.71%)
NIO   3.80 (-5.00%)
BABA   69.02 (+0.20%)
T   16.47 (+0.86%)
F   12.09 (+0.25%)
MU   106.31 (-5.02%)
GE   148.30 (-3.03%)
CGC   8.02 (+2.43%)
DIS   112.11 (-0.28%)
AMC   3.14 (+7.53%)
PFE   25.96 (+2.24%)
PYPL   61.87 (-0.37%)
XOM   119.88 (+1.15%)
Free Trial
NASDAQ:AQXP

Aquinox Pharmaceuticals (AQXP) Stock Price, News & Analysis

→ Bitcoin Rockets To Record High But Buy THIS Instead (From Paradigm Press) (Ad)
Free AQXP Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$30.85
▼
$33.81
50-Day Range
$3.68
▼
$4.03
52-Week Range
$2.00
▼
$3.84
Volume
100,284 shs
Average Volume
239,362 shs
Market Capitalization
$743.39 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisCompetitorsSocial Media
AQXP stock logo

About Aquinox Pharmaceuticals Stock (NASDAQ:AQXP)

Aquinox Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in developing novel therapeutics for chronic urological conditions by inflammation and pain. The company focuses on a library of novel compounds that activate SH2-containing inositol-5'-phosphatase 1 (SHIP1) to develop therapeutics for application in inflammation, inflammatory pain, and blood cancers. Its lead product candidate is Rosiptor (Leadership 301), a small molecule activator of SHIP1 that is in Phase III clinical trials for treatment in interstitial cystitis/bladder pain syndrome. The company was formerly known as Aquinox Pharmaceuticals (USA) Inc. and changed its name to Aquinox Pharmaceuticals, Inc. in January 2014. Aquinox Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

AQXP Stock News Headlines

February 11, 2024 | finance.yahoo.com
Mirum Pharmaceuticals, Inc. (MIRM)
September 24, 2023 | finance.yahoo.com
Why Aquinox Pharma (AQXP) Stock Might be a Great Pick
April 19, 2024 | Paradigm Press (Ad)
Bitcoin Rockets To Record High But Buy THIS Instead
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
July 26, 2023 | thestreet.com
Aquinox Pharmaceuticals (AQXP) Stock Jumping in After-Hours Trading Following Earnings Beat
June 9, 2022 | seekingalpha.com
Aquinox Pharma's lead product candidate flunks mid-stage trial in COPD; shares plummet 70%
See More Headlines
Receive AQXP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aquinox Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2018
Today
4/19/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AQXP
CUSIP
N/A
CIK
1404644
Web
www.aqxpharma.com
Phone
604-629-9223
Fax
N/A
Employees
8
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-31,580,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-30.13%
Return on Assets
-28.08%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
63.17
Quick Ratio
63.17

Sales & Book Value

Annual Sales
$25 million
Price / Sales
29.74
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.09 per share
Price / Book
10.22

Miscellaneous

Outstanding Shares
23,540,000
Free Float
N/A
Market Cap
$743.39 million
Optionable
Not Optionable
Beta
-7.37
5G Stocks: The Path Forward is Profitable Cover
5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. David J. Main (Age 54)
    Co-Founder, Chairman, CEO & Pres
  • Mr. Kamran Alam (Age 45)
    CFO, VP of Fin. & Corp. Sec.
  • Ms. Shelley McCloskey (Age 59)
    VP of HR & Admin.

Key Competitors

View All Competitors

AQXP Stock Analysis - Frequently Asked Questions

How were Aquinox Pharmaceuticals' earnings last quarter?

Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) announced its earnings results on Thursday, November, 8th. The company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.21) by $0.43.

What other stocks do shareholders of Aquinox Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aquinox Pharmaceuticals investors own include Novavax (NVAX), Bausch Health Companies (BHC), Sarepta Therapeutics (SRPT), ACADIA Pharmaceuticals (ACAD), Gilead Sciences (GILD), XOMA (XOMA), Alnylam Pharmaceuticals (ALNY), Inovio Pharmaceuticals (INO), SodaStream International (SODA) and ZIOPHARM Oncology (ZIOP).

This page (NASDAQ:AQXP) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
The “Perfect Storm” for Gold
Gold Safe Exchange
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
Biden’s $374B Giveaway Into This Sector
DTI
Your Money is Not Safe
American Alternative
He Is Giving Away Bitcoin
Crypto Swap Profits
The #1 Crypto for 2024
InvestorPlace
SHOCKING Crypto Leak…
Crypto 101 Media
My biggest AI fear
Paradigm Press